Kiromic BioPharma Inc

NASDAQ:KRBP  
7.71
-0.29 (-3.62%)
Products, Other Pre-Announcement

Kiromic To Resubmit Two Expanded Inds To The FDA For Its Allogenic, Off-The-Shelf Gamma-Delta T Cell Therapies For Multiple Solid Tumors

Published: 03/09/2021 22:11 GMT
Kiromic BioPharma Inc (KRBP) - Kiromic to Resubmit Two Expanded Inds to the FDA for Its Allogenic, Off-the-shelf Gamma-delta T Cell Therapies for Multiple Solid Tumors.
Kiromic Biopharma Inc - Revised Inds Have Protocols Which Retain Approximately 80% of Original Inds.
Kiromic Biopharma Inc - Sees 2q-2021 As Expected Timeline for Planned Two Ind Resubmissions.